All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
AACR 2017 | Poster 2651/10 – huB4-DGN462, a novel CD19 targeting antibody drug conjugate, shows promising activity in CD19+ Lymphoma models
On Monday 3rd April at this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2651 / 10) by Eugenio Gaudio, from the Institute of Oncology Research, Bellinzona, Switzerland, et al. titled “A novel CD19 targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models” was presented.
The group investigated the preclinical activity of a novel CD19-specifc ADC, consisting of the humanized anti-CD19 antibody huB4 and DGN462 via a cleavable disulfide linker, sulfo-SPDB. Activity of the huB4-DGN462 ADC or the unconjugated DGN462 toxin was measured in vitro using a total of 54 Lymphoma cell lines (n = 27 DLBCL; n = 10 MCL; n = 6 MZL; n = 5 ALCL; n = 6 others). Efficacy of huB4-DGN462 was also analyzed in vivo in CD19-expressing xenograft tumor models.
Key Highlights:
- huB4-DGN462 was cytotoxic in 48 B-cell Lymphoma lines (median IC50 100pM; 95%CI, 38–214)
- Cytotoxic activity was not associated with DLBCL cell of origin, or limited by P53, BCL2, MYC, or CDKN2A status
- huB4-DGN462 was significantly (P = 0.007) less active in 8 TCL lines (median IC50 75nM; 95% CI, 0.5–5.75) than in B-cell Lymphoma; in accordance with the lower CD19 expression in TCLs
- huB4-DGN462 induced caspase 3/7 activation in 89% (48/54) cell lines
- In two DLBCL xenograft models (DoHH2 SC model and Farage disseminated model), huB4-DGN462 showed strong anti-tumor activity after a single IV dose
- In DoHH2 model, at 1.7mg Ab/kg, huB4-DGN462 lead to a significant, dose-dependent delay in tumor growth and survival benefit versus a non-targeted control DGN462 ADC
- In Farage model, a significant, dose-dependent increase in survival was reported in mice treated with as little as 0.17mg Ab/kg of huB4-DGN462; At 1.7mg Ab/kg, life span increased by >400% versus untreated mice
The poster concluding by stating that this data indicates that the novel ADC huB4-DGN462 has potent activity in preclinical models, providing cause for further study.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?